Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (15965)	3/2/1999 12:10:00 AM
From: Nazbuster	Read Replies (2) \| Respond to of 122087

Anthony, don't you love it when people POST they have inside info... #reply-8098255

To: Anthony@Pacific who wrote (15965)	3/2/1999 1:06:00 AM
From: Nazbuster	Read Replies (2) \| Respond to of 122087

Anthony, since you know the drug co's well, what do you think of ZONA? They make a product less effective (but possibly safer) than viagra. Not yet approved by FDA, but they just entered mfg. agreement with Schering Plough. Possible short? News: biz.yahoo.com Quote/chart: quote.yahoo.com 11/16/98 10Q: sec.yahoo.com WSRN info: wsrn.com *Schering-Plough commenced sales of Vasomax(R) in Mexico under the brand name of Z-Max in June 1998.* Nothing like some guinea pigs prior to FDA approval! Nice ethics! The Company has experienced negative cash flows from operations since its inception and has funded its activities to date primarily from equity financings and corporate collaborative agreements. ... The Company's ability to raise additional funds in the public or private markets will be adversely affected if the results of its current or future clinical trials and the commercialization of Vasomax(R) are not favorable. The Company may seek additional funding through corporate collaborations and other financing vehicles.